PitchSend

Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 7 Sales growth is primarily driven by 18% growth in GLP-1 sales, while global insulin sales is broadly unchanged 9M 2018 reported sales split and local currency growth for NAO and IO 9M 2018 added sales and local currency growth for NAO and IO Insulin GLP-1 Other diabetes care DKK billion Obesity Biopharm International Operations North America Operations Group local currency growth 50 Therapy areas DKK billion 1% 8% International Operations regions 4% -1% 18% 53% -1% 4 40 3 15% 30 2 8% 18% 20 1 2% 6% 1% 139% 31% 0 14% 8% 4% -8% 10 -3% 35% -1 -8% -2 NAO IO Region Region Region Region Region Europe AAMEO China J&K LATAM Total Insulin GLP-1 Obesity Biopharm NAO: North America Operations; IO: International Operations; LATAM: Latin America; AAMEO: Africa, Asia, Middle East & Oceania; J&K: Japan & Korea; 9M: First nine months of 2018 1 "Other diabetes care" is included in Total. novo nordisk

View entire presentation